We invest in the future of medicine and technology
We combine science, technology and capital to create breakthrough solutions for health and life.
We create science and innovation.
Siemionow BioMed Ventures (SBMV) invests in the frontier of science with the goal of increasing healthy lifespan. We build companies that harness the power of computation to advance medicine. We back scientists, engineers, and founders developing technologies that diagnose and predict disease, regenerate and regulate biological systems, restore or augment the body, and relieve pain — all to improve function and sustain physiological homeostasis.
From synthetic biology and neural interfaces to intelligent diagnostics and regenerative therapeutics, we build companies or partner with founders shaping the next biological revolution — transforming how humans heal, move, and evolve.
Dr. Kris Siemionow, MD, PhD
Dr. Kris Siemionow, MD. PhD is an entrepreneur and retired board-certified spine surgeon, who founded and co-founded multiple medical companies, that utilize advanced technology to improve clinical outcomes.
Dr. Siemionow is the founder and principal of Siemionow Biomed Ventures (SBMV), a life-sciences and deep technology focused fund investing in the most breakthrough ideas that will revolutionize healthcare.
Prior to starting his capital group, Dr. Siemionow was a board-certified spine surgeon and Tenured Associate Professor of Neurosurgery and Orthopedic Surgery at the University of Illinois in Chicago.
News and publications
Stay up to date with the latest information about our investments, partnerships and industry events.
January 20, 2026 Medicalgorithmics strengthens Shareholder structure. Investors acquire shares worth nearly PLN 70 million
January 15, 2026 VB Spine to Acquire Intraoperative Visualization Platform from Robotron Surgical Technologies
September 01, 2025 Medicalgorithmics S A : Investors acquire nearly PLN 50 million worth of Medicalgorithmics shares
September 01, 2025 Duże zmiany w akcjonariacie Medicalgorithmics. Biofund sprzedał 15 proc.
February 10, 2025 Medicalgorithmics’ DeepRhythmAI (DRAI), Revolutionizes Heart Diagnosis
December 11, 2024 Capstan Medical Secures $110M to Bring First-of-its-Kind Robotics Technology to Heart Disease Patients
October 24, 2024 Medicalgorithmics has achieved another milestone. Certification for its DeepRhythm Platform in Canada.
October 17, 2024 Medicalgorithmics obtains CE certification for VCAST technology
June 26, 2024 Biofund Capital Management LLC, a Siemionow Ventures Portfolio Company, Announces $3M Line of Credit Facility to Support Rapid Growth of Medicalgorithmics
April 29, 2024 Medicalgorithmics is pleased to announce that its subsidiary, Kardiolytics, has been granted a new patent in the United States for a method of numerical modeling of blood flow in arteries.
December 20, 2023 16:48 ET Dystrogen Therapeutics Announces Approval of Clinical Trial Application (CTA) to Initiate a Phase 1/2 Clinical Trial of DT-DEC01 for the Treatment of Duchenne Muscular Dystrophy
September 17, 2023 07:04 ET Dystrogen Therapeutics Corp announces new publication “Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 – Month Follow-Up Study After Systemic Intraosseous Administration”
September 8, 2023 23:26 ET Capstan Medical hauls in $31M to develop robotic transcatheter heart valve replacements
September 7, 2023 19:36 ET Analyst Coverage Initiated for Medicalgorithmics with BUY rating
January 23, 2023 16:49 ET Dystrogen Therapeutics Corp Announces Presentation of Abstracts at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
October 1, 2022 20:06 ET Conclusion of an investment agreement regarding the acquisition of new shares in the Company for a contribution of approximately PLN 220 million (PLN 44.27 per share).
September 29, 2022 20:07 ET Clinical Catch-Up: NASH, DMD Spaces Continue to Accelerate
September 26, 2022 20:07 ET Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for Duchenne Muscular Dystrophy Demonstrates Clinically Significant Functional and Biomarker Improvements
April 7, 2022 20:08 ET Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for the Treatment of Duchene Muscular Dystrophy Shows Safety and Functional Improvements
January 18, 2022 21:44 ET Surgalign Receives FDA Clearance for HOLO Portal™ System, the World’s First AI-driven AR Guidance System for Spine Surgery
January 4, 2022 20:08 ET Dystrogen Therapeutics Announces First in Man Dosing of Novel Chimeric Cell Therapy for Duchenne Muscular Dystrophy and Reports 6-week Clinical Outcomes
October 23, 2020 20:08 ET Surgalign Holdings, Inc. Announces Completion of Acquisition of Holo Surgical Inc. and its ARAI Digital Surgery Platform
October 23, 2020 20:08 ET Surgalign Holdings, Inc. Expands Digital Health Capabilities with Acquisition of a Significant Equity Interest in Inteneural Networks Inc.
Dystrogene Gene Therapy Shows Promise for Huntington’s
January 9, 2019 20:09 ET HoloSurgical Inc, a Digital Surgery Company, Announces First Surgical Procedure Utilizing the ARAI™, an Augmented Reality and Artificial Intelligence Based Surgical Navigation System
